Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 17 studies | 29% ± 11% | |
fibroblast | 13 studies | 23% ± 9% | |
astrocyte | 12 studies | 31% ± 13% | |
oligodendrocyte precursor cell | 11 studies | 34% ± 15% | |
microglial cell | 10 studies | 29% ± 11% | |
macrophage | 9 studies | 31% ± 11% | |
smooth muscle cell | 9 studies | 23% ± 6% | |
oligodendrocyte | 9 studies | 29% ± 10% | |
myeloid cell | 8 studies | 26% ± 6% | |
adipocyte | 8 studies | 22% ± 5% | |
type I pneumocyte | 8 studies | 21% ± 6% | |
glutamatergic neuron | 7 studies | 42% ± 23% | |
pericyte | 7 studies | 26% ± 12% | |
monocyte | 7 studies | 25% ± 7% | |
GABAergic neuron | 7 studies | 42% ± 17% | |
natural killer cell | 6 studies | 19% ± 3% | |
interneuron | 6 studies | 39% ± 19% | |
epithelial cell | 6 studies | 40% ± 18% | |
retina horizontal cell | 6 studies | 22% ± 4% | |
ciliated cell | 6 studies | 27% ± 9% | |
type II pneumocyte | 6 studies | 22% ± 6% | |
B cell | 5 studies | 21% ± 3% | |
classical monocyte | 5 studies | 31% ± 11% | |
neuron | 5 studies | 45% ± 13% | |
amacrine cell | 5 studies | 22% ± 3% | |
retinal cone cell | 5 studies | 23% ± 6% | |
retinal rod cell | 5 studies | 26% ± 6% | |
cardiac muscle cell | 5 studies | 40% ± 9% | |
dendritic cell | 5 studies | 28% ± 12% | |
endothelial cell of lymphatic vessel | 5 studies | 27% ± 7% | |
club cell | 5 studies | 25% ± 8% | |
squamous epithelial cell | 4 studies | 33% ± 19% | |
CD16-positive, CD56-dim natural killer cell, human | 4 studies | 18% ± 1% | |
CD4-positive, alpha-beta T cell | 4 studies | 18% ± 2% | |
non-classical monocyte | 4 studies | 27% ± 13% | |
granule cell | 4 studies | 23% ± 7% | |
myofibroblast cell | 4 studies | 25% ± 6% | |
retinal bipolar neuron | 4 studies | 20% ± 2% | |
lymphocyte | 4 studies | 28% ± 8% | |
Mueller cell | 4 studies | 19% ± 4% | |
T cell | 4 studies | 20% ± 1% | |
goblet cell | 4 studies | 35% ± 25% | |
effector memory CD8-positive, alpha-beta T cell | 3 studies | 18% ± 4% | |
hematopoietic precursor cell | 3 studies | 29% ± 6% | |
plasmablast | 3 studies | 28% ± 8% | |
glial cell | 3 studies | 26% ± 7% | |
plasma cell | 3 studies | 32% ± 8% | |
mast cell | 3 studies | 20% ± 6% | |
mononuclear phagocyte | 3 studies | 23% ± 4% | |
GABAergic amacrine cell | 3 studies | 20% ± 1% | |
glycinergic amacrine cell | 3 studies | 23% ± 1% | |
hepatocyte | 3 studies | 35% ± 20% | |
muscle cell | 3 studies | 40% ± 23% | |
CD8-positive, alpha-beta T cell | 3 studies | 20% ± 4% | |
abnormal cell | 3 studies | 32% ± 14% | |
neutrophil | 3 studies | 26% ± 10% | |
alveolar macrophage | 3 studies | 28% ± 9% | |
basal cell | 3 studies | 37% ± 16% | |
transit amplifying cell | 3 studies | 35% ± 24% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 7546.17 | 1445 / 1445 | 100% | 20.39 | 183 / 183 |
stomach | 100% | 6898.76 | 359 / 359 | 100% | 17.87 | 286 / 286 |
lung | 100% | 7686.66 | 578 / 578 | 99% | 17.68 | 1148 / 1155 |
intestine | 100% | 7059.58 | 966 / 966 | 99% | 15.98 | 523 / 527 |
ovary | 100% | 8301.32 | 180 / 180 | 99% | 16.99 | 426 / 430 |
brain | 99% | 4514.35 | 2603 / 2642 | 99% | 24.77 | 698 / 705 |
skin | 100% | 8822.07 | 1809 / 1809 | 97% | 18.83 | 459 / 472 |
breast | 100% | 6813.87 | 459 / 459 | 97% | 21.86 | 1083 / 1118 |
bladder | 100% | 7489.05 | 21 / 21 | 96% | 17.99 | 486 / 504 |
prostate | 100% | 7217.73 | 245 / 245 | 96% | 20.57 | 480 / 502 |
thymus | 100% | 8855.96 | 653 / 653 | 95% | 18.47 | 575 / 605 |
pancreas | 100% | 4347.39 | 328 / 328 | 95% | 15.20 | 169 / 178 |
kidney | 100% | 5724.30 | 89 / 89 | 94% | 13.63 | 847 / 901 |
uterus | 100% | 8273.69 | 170 / 170 | 92% | 15.85 | 422 / 459 |
liver | 100% | 5668.07 | 226 / 226 | 87% | 12.50 | 352 / 406 |
adrenal gland | 100% | 5176.76 | 258 / 258 | 80% | 6.72 | 184 / 230 |
adipose | 100% | 6876.31 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 9180.13 | 1335 / 1335 | 0% | 0 | 0 / 0 |
muscle | 100% | 17405.33 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 8039.20 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 3.62 | 1 / 1 |
peripheral blood | 100% | 12414.21 | 926 / 929 | 0% | 0 | 0 / 0 |
heart | 98% | 8728.70 | 847 / 861 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 96% | 19.95 | 43 / 45 |
eye | 0% | 0 | 0 / 0 | 94% | 10.66 | 75 / 80 |
lymph node | 0% | 0 | 0 / 0 | 66% | 11.90 | 19 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0043154 | Biological process | negative regulation of cysteine-type endopeptidase activity involved in apoptotic process |
GO_0035994 | Biological process | response to muscle stretch |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0038133 | Biological process | ERBB2-ERBB3 signaling pathway |
GO_0042552 | Biological process | myelination |
GO_0000165 | Biological process | MAPK cascade |
GO_0048011 | Biological process | neurotrophin TRK receptor signaling pathway |
GO_0048009 | Biological process | insulin-like growth factor receptor signaling pathway |
GO_0007165 | Biological process | signal transduction |
GO_0033138 | Biological process | positive regulation of peptidyl-serine phosphorylation |
GO_0031333 | Biological process | negative regulation of protein-containing complex assembly |
GO_0008625 | Biological process | extrinsic apoptotic signaling pathway via death domain receptors |
GO_0060333 | Biological process | type II interferon-mediated signaling pathway |
GO_0030878 | Biological process | thyroid gland development |
GO_0043410 | Biological process | positive regulation of MAPK cascade |
GO_0035773 | Biological process | insulin secretion involved in cellular response to glucose stimulus |
GO_0042060 | Biological process | wound healing |
GO_0071550 | Biological process | death-inducing signaling complex assembly |
GO_0007190 | Biological process | activation of adenylate cyclase activity |
GO_0008286 | Biological process | insulin receptor signaling pathway |
GO_0042981 | Biological process | regulation of apoptotic process |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0014044 | Biological process | Schwann cell development |
GO_0045595 | Biological process | regulation of cell differentiation |
GO_0060324 | Biological process | face development |
GO_0035023 | Biological process | regulation of Rho protein signal transduction |
GO_0045104 | Biological process | intermediate filament cytoskeleton organization |
GO_0048538 | Biological process | thymus development |
GO_2000145 | Biological process | regulation of cell motility |
GO_0006915 | Biological process | apoptotic process |
GO_1902042 | Biological process | negative regulation of extrinsic apoptotic signaling pathway via death domain receptors |
GO_0006468 | Biological process | protein phosphorylation |
GO_0044342 | Biological process | type B pancreatic cell proliferation |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0035019 | Biological process | somatic stem cell population maintenance |
GO_0005886 | Cellular component | plasma membrane |
GO_0005739 | Cellular component | mitochondrion |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0031143 | Cellular component | pseudopodium |
GO_0005741 | Cellular component | mitochondrial outer membrane |
GO_0005634 | Cellular component | nucleus |
GO_0019899 | Molecular function | enzyme binding |
GO_0106310 | Molecular function | protein serine kinase activity |
GO_0004674 | Molecular function | protein serine/threonine kinase activity |
GO_0042802 | Molecular function | identical protein binding |
GO_0031267 | Molecular function | small GTPase binding |
GO_0004672 | Molecular function | protein kinase activity |
GO_0004709 | Molecular function | MAP kinase kinase kinase activity |
GO_0046872 | Molecular function | metal ion binding |
GO_0005524 | Molecular function | ATP binding |
GO_0005515 | Molecular function | protein binding |
Gene name | RAF1 |
Protein name | Eosinophil cationic protein (Ribonuclease 3) Raf-1 proto-oncogene, serine/threonine kinase non-specific serine/threonine protein kinase (EC 2.7.11.1) (Proto-oncogene c-RAF) RAF proto-oncogene serine/threonine-protein kinase (EC 2.7.11.1) (Proto-oncogene c-RAF) (cRaf) (Raf-1) RAF proto-oncogene serine/threonine-protein kinase (EC 2.7.11.1) (Proto-oncogene c-RAF) (Raf-1) non-specific serine/threonine protein kinase (EC 2.7.11.1) |
Synonyms | hCG_40478 RAF RNASE3 |
Description | FUNCTION: Serine/threonine-protein kinase that acts as a regulatory link between the membrane-associated Ras GTPases and the MAPK/ERK cascade, and this critical regulatory link functions as a switch determining cell fate decisions including proliferation, differentiation, apoptosis, survival and oncogenic transformation. RAF1 activation initiates a mitogen-activated protein kinase (MAPK) cascade that comprises a sequential phosphorylation of the dual-specific MAPK kinases (MAP2K1/MEK1 and MAP2K2/MEK2) and the extracellular signal-regulated kinases (MAPK3/ERK1 and MAPK1/ERK2). The phosphorylated form of RAF1 (on residues Ser-338 and Ser-339, by PAK1) phosphorylates BAD/Bcl2-antagonist of cell death at 'Ser-75'. Phosphorylates adenylyl cyclases: ADCY2, ADCY5 and ADCY6, resulting in their activation. Phosphorylates PPP1R12A resulting in inhibition of the phosphatase activity. Phosphorylates TNNT2/cardiac muscle troponin T. Can promote NF-kB activation and inhibit signal transducers involved in motility (ROCK2), apoptosis (MAP3K5/ASK1 and STK3/MST2), proliferation and angiogenesis (RB1). Can protect cells from apoptosis also by translocating to the mitochondria where it binds BCL2 and displaces BAD/Bcl2-antagonist of cell death. Regulates Rho signaling and migration, and is required for normal wound healing. Plays a role in the oncogenic transformation of epithelial cells via repression of the TJ protein, occludin (OCLN) by inducing the up-regulation of a transcriptional repressor SNAI2/SLUG, which induces down-regulation of OCLN. Restricts caspase activation in response to selected stimuli, notably Fas stimulation, pathogen-mediated macrophage apoptosis, and erythroid differentiation. . |
Accessions | A0A8I5KSV6 ENST00000691899.1 [P04049-1] ENST00000685653.1 [P04049-1] ENST00000690585.1 ENST00000685437.1 A0A8I5KSI1 ENST00000685738.1 ENST00000687326.1 ENST00000692959.1 ENST00000432427.3 A0A8I5KQV4 A0A8I5KW44 A0A8I5KS16 ENST00000692093.1 ENST00000686762.1 A0A8I5KUW4 ENST00000689033.1 ENST00000689481.1 ENST00000423275.6 A0A8I5QKU8 ENST00000691724.1 ENST00000416093.2 A0A8I5KTA5 A0A0S2Z559 ENST00000693705.1 A0A8I5QKZ6 ENST00000691396.1 ENST00000689914.1 ENST00000685348.1 ENST00000690397.1 A0A8I5KX50 ENST00000691718.1 A0A8I5KT32 A0A8I5KR46 A0A8I5KYC4 A0A0S2Z4L5 ENST00000687486.1 A0A8I5QJG5 ENST00000442415.7 [P04049-2] A0A8I5KTK4 ENST00000690460.1 ENST00000688543.1 ENST00000251849.9 [P04049-1] A0A8I5KSB0 ENST00000687923.1 W0UUR6 ENST00000691779.1 A0A0B4J1W9 A0A8I5KWF7 A0A8I5KSM4 ENST00000688625.1 ENST00000689876.1 A0A8I5KWS9 ENST00000689097.1 ENST00000689226.1 ENST00000693069.1 ENST00000693312.1 ENST00000691268.1 ENST00000688326.1 H7C155 ENST00000688753.1 A0A8I5KYP5 ENST00000693664.1 P04049 ENST00000684903.1 ENST00000689389.1 ENST00000687348.1 ENST00000691888.1 ENST00000685959.1 A0A8I5KQ33 A0A8I5KRD1 A0A8I5KWA9 ENST00000685740.1 ENST00000689418.1 ENST00000692773.1 ENST00000692830.1 L7RRS6 |